Probiotic Characterization of Cholesterol-Lowering Lactobacillus fermentum MJM60397
- PMID: 31432401
- DOI: 10.1007/s12602-019-09585-y
Probiotic Characterization of Cholesterol-Lowering Lactobacillus fermentum MJM60397
Abstract
Lactobacillus fermentum MJM60397 was subjected to in vitro safety tests and in vivo probiotic characterization. The MJM60397 strain was susceptible to antibiotics and was found to be non-mucinolytic and non-hemolytic, and does not produce bioamines. In addition, MJM60397 tolerated simulated oro-gastrointestinal conditions and adhered to Caco-2 cells. MJM60397 also exhibited bile salt hydrolase activity and could deconjugate bile acids. The hypocholesterolemic effects of strain MJM60397 were studied in high-fat diet-induced hypercholesterolemic male ICR mice. The mice were fed a high-cholesterol diet (HCD) and were divided into the following three experimental groups: HCD-control (HCD-Con), mice fed with HCD + L. fermentum MJM60397 (HCD-MJM60397), and mice fed with HCD + L. acidophilus ATCC 43121 (HCD-L.ac) as the positive control. Simultaneously, a normal control diet (NCD) group was maintained. After 7 weeks, the total cholesterol and low-density lipoprotein (LDL) cholesterol levels were significantly reduced in the livers of the HCD-MJM60397 mice when compared to those in the HCD-Con and HCD-L.ac mice. Fecal total bile acid content was significantly (P < 0.05) higher in the HCD-MJM60397 group than in the NCD, HCD-Con, and HCD-L.ac groups. Analysis of gene expression revealed higher expression of LDLR gene in the livers of the HCD-MJM60397 and HCD-L.ac mice than in the livers of the HCD-Con mice. These findings show that the hypocholesterolemic effects of the MJM60397 strain were attributable to its bile salt deconjugating activity, which resulted in decreased bile acid absorption and increased excretion of bile acids in the feces. These results indicate that L. fermentum MJM60397 could be developed into a potential probiotic for reducing the serum cholesterol levels.
Keywords: Bile salt hydrolase; Cholesterol-lowering activity; LDL cholesterol; Lactobacillus fermentum; Probiotics.
References
-
- Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, Calder PC, Sanders ME (2014) Expert consensus document: the International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 11:506–514. https://doi.org/10.1038/nrgastro.2014.66 - DOI
-
- Critchfield JW, van Hemert S, Ash M, Mulder L, Ashwood P (2011) The potential role of probiotics in the management of childhood autism spectrum disorders. Gastroenterol Res Pract 2011:161358:1–8. https://doi.org/10.1155/2011/161358 - DOI
-
- Drisko JA, Giles CK, Bischoff BJ (2003) Probiotics in health maintenance and disease prevention. Altern Med Rev 8(2):143–155 - PubMed
-
- Tripathi MK, Giri SK (2014) Probiotic functional foods: survival of probiotics during processing and storage. J Funct Foods 9:225–241. https://doi.org/10.1016/j.jff.2014.04.030 - DOI
-
- Bhatnagar D, Soran H, Durrington PN (2008) Hypercholesterolaemia and its management. BMJ 337:a993. https://doi.org/10.1136/bmj.a993 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
